Search

FDA Panel Backs Amgen Bone Drug, Says Benefits Outweigh Heart Risks

FDA PANEL BACKS AMGEN BONE DRUG, SAYS BENEFITS OUTWEIGH HEART RISKS

An experimental Amgen osteoporosis drug that had sparked concern about cardiovascular side effects has won the backing of an FDA advisory...

ROCHE R&D EXEC BEGINS A NEW VOYAGE WITH BIOTECH MOVE

Another day, another Big Pharma exec jumps ship to biotech: This morning, it's Omar Khwaja, M.D., Ph.D., who becomes chief medical...

 
 
 

AFTER JPM, BIOTECHS STILL SCRAMBLING FOR IPOS AS KALEIDO, CIRIUS FILE AMID GOVERNMENT SHUTDOWN

We saw a flurry of initial public offering activity in the lead-up to the J.P. Morgan Healthcare Conference, but it seems as the dust...

 
 
 

PRODUCTION SCIENTIST - CUE HEALTH - SAN DIEGO, CA

Utilizes bio-analytical methods (analytical chemistry, biochemistry, biotechnology, immunology, microbiology, molecular biology, or...

 
 
 
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More

NOTES FROM THE JPM19 VORTEX: PRICE APOCALYPSE, CELGENE FALLOUT & MORE

[ Editor's note: Ben Fidler and Sarah de Crescenzo coauthored this report .] It is here, and then it is gone. But by the time everyone...

 
 
 
Tetra Inks Deal with Shionogi to Support Fragile X, Alzheimer's R&D

TETRA INKS DEAL WITH SHIONOGI TO SUPPORT FRAGILE X, ALZHEIMER'S R&D

The lead drug of Tetra Discovery Partners is already in mid-stage clinical studies as a treatment for the rare Fragile X Syndrome....

PEPTALK: THE PROTEIN SCIENCE WEEK

PepTalk: The Protein Science Week is one of the largest annual gatherings of protein science researchers in the world. Now, in its...

 
 
 
Trending News on Crop Biotech in 2018

TRENDING NEWS ON CROP BIOTECH IN 2018

What GM crop can be used to treat AIDS? Which country would be the first one to plant drought and salt tolerant soybean? What are the...

Biotech Crops Show Sustained Growth and Benefits in 2014; Global Plantings Increase by 6 Million Hectares

BIOTECH CROPS SHOW SUSTAINED GROWTH AND BENEFITS IN 2014; GLOBAL PLANTINGS INCREASE BY 6 MILLION HECTARES

The 2014 Global Status of Commercialized Biotech/GM Crops , authored by Clive James, Founder and Emeritus Chair of ISAAA, reports that...

 
 
 
Sunrise of Hope for Small-Scale Biotech Farmers

SUNRISE OF HOPE FOR SMALL-SCALE BIOTECH FARMERS

The poet Jean Marble makes a plea in behalf of farmers: Make sunrise early and the sunset wait; Make summer early and the winter late! Allow...

Global Status of Commercialized Biotech/GM Crops 2014 Launched in Beijing; Media Conferences Held in Asian Countries

GLOBAL STATUS OF COMMERCIALIZED BIOTECH/GM CROPS 2014 LAUNCHED IN BEIJING; MEDIA CONFERENCES HELD IN ASIAN COUNTRIES

Since 1996, during the first year of commercialization of biotech crops, ISAAA has released the annual “Global Status of Commercialized...

 
 
 

POSEIDA PITCHES A $115M IPO ON ITS CLAIM THAT THE SCIENCE TEAM HAS CREATED A BETTER BCMA CAR-T

Is there enough enthusiasm among biotech investors to push through a $115 million-plus IPO on the latest biotech staking out their...

ARCHITECT, ENTRY LEVEL - CLARK RICHARDSON & BISKUP - SAN DIEGO, CA

Experience with advanced technology industry projects preferred such as R&D labs, biotechnology, pharmaceutical, food & nutrition,...

 
 
 
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More

BIO ROUNDUP: $74B FOR CELGENE, TWO CAR-T TALES, READY FOR SF & MORE

In 2018, my Exome colleagues and I published hundreds of stories about health, medicine, the biopharma industry, government policy,...

Sophia Genetics bags $77M Series E, with 850+ hospitals signed up to its “data-driven medicine”

SOPHIA GENETICS BAGS $77M SERIES E, WITH 850+ HOSPITALS SIGNED UP TO ITS “DATA-DRIVEN MEDICINE”

Another sizeable cash injection for big data biotech: Sophia Genetics has announced a $77M Series E funding round, bringing its total...

 
 
 
Alphabet's Biotech R&D Arm Verily Raises $1B to Fuel Growth

ALPHABET'S BIOTECH R&D ARM VERILY RAISES $1B TO FUEL GROWTH

Verily, the biotech research and development company owned by Google parent Alphabet, has raised $1 billion in an investment round...

Here's why Bristol-Myers Squibb's record-breaking $74 billion biotech deal is facing investor backlash

HERE'S WHY BRISTOL-MYERS SQUIBB'S RECORD-BREAKING $74 BILLION BIOTECH DEAL IS FACING INVESTOR BACKLASH

Bristol-Myers Squibb said on Thursday that it would acquire the biotech Celgene in a $74 billion deal . The two companies each face...